Curcumin for chemoprevention of colon cancer

Cancer Letters

Volumn 255, Issue 2, 2007, Pages 170-181

  Johnson, Jeremy James ^a,b   Mukhtar, Hasan ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Cancer; Chemoprevention; Colon; COX 2; Curcumin; Turmeric

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CURCUMIN; CYCLOOXYGENASE 2; EARLY GROWTH RESPONSE FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; NITRIC OXIDE SYNTHASE; PIPERINE; PROTEIN KINASE C; PROTEIN SERINE THREONINE KINASE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; CANCER PREVENTION; CELL CYCLE ARREST; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CURCUMA LONGA; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; NAUSEA; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT;

ANIMALIA; CURCUMA LONGA;

EID: 34547948369     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.03.005     Document Type: Review

References (77)

1. Khan N., Afaq F., and Mukhtar H. Apoptosis by dietary factors: the suicide solution for delaying cancer growth. Carcinogenesis (2006)
2. Aggarwal B.B., Kumar A., and Bharti A.C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 23 (2003) 363-398
3. Pisani P., Bray F., and Parkin D.M. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int. J. Cancer 97 (2002) 72-81
4. Calvert P.M., and Frucht H. The genetics of colorectal cancer. Ann. Intern. Med. 137 (2002) 603-612
5. Potter J.D. Colorectal cancer: molecules and populations. J. Natl. Cancer Inst. 91 (1999) 916-932
6. Thun M.J., Henley S.J., and Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. 94 (2002) 252-266
7. Levin B., Barthel J.S., Burt R.W., et al. Colorectal cancer screening clinical practice guidelines. J. Natl. Compr. Canc. Netw. 4 (2006) 384-420
8. Brophy J., Levesques L., and Zhang B. The coronary risk of cyclooxygenase-2 (Cox-2) inhibitors in subjects with a previous myocardial infarction. Heart (2006)
9. Du B., Jiang L., Xia Q., and Zhong L. Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29. Chemotherapy 52 (2006) 23-28
10. Lev-Ari S., Strier L., Kazanov D., et al. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin. Cancer Res. 11 (2005) 6738-6744
11. Lev-Ari S., Zinger H., Kazanov D., et al. Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. Biomed. Pharmacother. 59 Suppl. 2 (2005) S276-S280
12. Notarbartolo M., Poma P., Perri D., Dusonchet L., Cervello M., and D'Alessandro N. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-κB activation levels and in IAP gene expression. Cancer Lett. 224 (2005) 53-65
13. Koo J.Y., Kim H.J., Jung K.O., and Park K.Y. Curcumin inhibits the growth of AGS human gastric carcinoma cells in vitro and shows synergism with 5-fluorouracil. J. Med. Food 7 (2004) 117-121
14. Chan M.M., Fong D., Soprano K.J., Holmes W.F., and Heverling H. Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agents. J. Cell. Physiol. 194 (2003) 63-70
15. Hour T.C., Chen J., Huang C.Y., Guan J.Y., Lu S.H., and Pu Y.S. Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21(WAF1/CIP1) and C/EBPbeta expressions and suppressing NF-kappaB Activation. Prostate 51 (2002) 211-218
16. Liu Y., Chang R.L., Cui X.X., Newmark H.L., and Conney A.H. Synergistic effects of curcumin on all-trans retinoic acid- and 1 alpha, 25-dihydroxyvitamin D3-induced differentiation in human promyelocytic leukemia HL-60 cells. Oncol. Res. 9 (1997) 19-29
17. Leu T.H., and Maa M.C. The molecular mechanisms for the antitumorigenic effect of curcumin. Curr. Med. Chem. Anticancer Agents 2 (2002) 357-370
18. Collett G.P., and Campbell F.C. Curcumin induces c-jun N-terminal kinase-dependent apoptosis in HCT116 human colon cancer cells. Carcinogenesis 25 (2004) 2183-2189
19. Scott D.W., and Loo G. Curcumin-induced GADD153 gene up-regulation in human colon cancer cells. Carcinogenesis 25 (2004) 2155-2164
20. Kim D.G., You K.R., Liu M.J., Choi Y.K., and Won Y.S. GADD153-mediated anticancer effects of N-(4-hydroxyphenyl)retinamide on human hepatoma cells. J. Biol. Chem. 277 (2002) 38930-38938
21. Lengwehasatit I., and Dickson A.J. Analysis of the role of GADD153 in the control of apoptosis in NS0 myeloma cells. Biotechnol. Bioeng. 80 (2002) 719-730
22. Maytin E.V., Ubeda M., Lin J.C., and Habener J.F. Stress-inducible transcription factor CHOP/gadd153 induces apoptosis in mammalian cells via p38 kinase-dependent and -independent mechanisms. Exp. Cell Res. 267 (2001) 193-204
23. Collett G.P., and Campbell F.C. Curcumin induces c-jun N-terminal kinase-dependent apoptosis in HCT116 human colon cancer cells. Carcinogenesis 25 (2004) 2183-2189
24. Moussavi M., Assi K., Gomez-Munoz A., and Salh B. Curcumin mediates ceramide generation via the de novo pathway in colon cancer cells. Carcinogenesis (2006)
25. Rashmi R., Santhosh Kumar T.R., and Karunagaran D. Human colon cancer cells differ in their sensitivity to curcumin-induced apoptosis and heat shock protects them by inhibiting the release of apoptosis-inducing factor and caspases. FEBS Lett. 538 (2003) 19-24
26. Jaiswal A.S., Marlow B.P., Gupta N., and Narayan S. Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 21 (2002) 8414-8427
27. Moragoda L., Jaszewski R., and Majumdar A.P. Curcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cells. Anticancer Res. 21 (2001) 873-878
28. Chen H., Zhang Z.S., Zhang Y.L., and Zhou D.Y. Curcumin inhibits cell proliferation by interfering with the cell cycle and inducing apoptosis in colon carcinoma cells. Anticancer Res. 19 (1999) 3675-3680
29. Fujii-Kuriyama Y., and Mimura J. Molecular mechanisms of AhR functions in the regulation of cytochrome P450 Genes. Biochem. Biophys. Res. Commun. 338 (2005) 311-317
30. Rinaldi A.L., Morse M.A., Fields H.W., et al. Curicumin activates the aryl hydrocarbon receptor yet significantly inhibits (-)-benzo(a)pyrene-7R-trans-7,8-dihydrodiol bioactivation in oral squamous cell carcinoma cells and oral mucosa. Cancer Res. 62 (2002) 5451-5456
31. Giuliani L., Ciotti M., Stoppacciaro A., et al. UDP-glucuronosyltransferases 1A expression in human urinary bladder and colon cancer by immunohistochemistry. Oncol. Rep. 13 (2005) 185-191
32. Basu N.K., Ciotti M., Hwang M.S., et al. Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J. Biol. Chem. 279 (2004) 1429-1441
33. Basu N.K., Kovarova M., Garza A., et al. Phosphorylation of a UDP-glucuronosyltransferase regulates substrate specificity. Proc. Natl. Acad. Sci. USA 102 (2005) 6285-6290
34. Lin J.K. Suppression of protein kinase C and nuclear oncogene expression as possible action mechanisms of cancer chemoprevention by curcumin. Arch. Pharm. Res. 27 (2004) 683-692
35. Gopalakrishna R., and Gundimeda U. Antioxidant regulation of protein kinase C in cancer prevention. J. Nutr. 132 (2002) 3819S-3823S
36. Maxhimer J.B., Reddy R.M., Zuo J., Cole G.W., Schrump D.S., and Nguyen D.M. Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (Trichostatin A) and protein kinase C inhibitor (calphostin C). J. Thorac. Cardiovasc. Surg. 129 (2005) 53-63
37. Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy - from molecular mechanisms to therapeutic benefits. Biochim. Biophys. Acta 1754 (2005) 253-262
38. De Smaele E., Zazzeroni F., Papa S., et al. Induction of gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signalling. Nature 414 (2001) 308-313
39. Tang G., Minemoto Y., Dibling B., et al. Inhibition of JNK activation through NF-kappaB target genes. Nature 414 (2001) 313-317
40. Jeong W.S., Kim I.W., Hu R., and Kong A.N. Modulation of AP-1 by natural chemopreventive compounds in human colon HT-29 cancer cell line. Pharm. Res. 21 (2004) 649-660
41. Yamamoto Y., and Gaynor R.B. Therapeutic potential of inhibition of the nf-kappab pathway in the treatment of inflammation and cancer. J. Clin. Invest. 107 (2001) 135-142
42. Sharma C., Kaur J., Shishodia S., Aggarwal B.B., and Ralhan R. Curcumin down regulates smokeless tobacco-induced NF-kappaB activation and COX-2 expression in human oral premalignant and cancer cells. Toxicology 228 (2006) 1-15
43. Jeong W.S., Kim I.W., Hu R., and Kong A.N. Modulatory properties of various natural chemopreventive agents on the activation of NF-kappaB signaling pathway. Pharm. Res. 21 (2004) 661-670
44. Plummer S.M., Holloway K.A., Manson M.M., et al. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 18 (1999) 6013-6020
45. Su C.C., Chen G.W., Lin J.G., Wu L.T., and Chung J.G. Curcumin inhibits cell migration of human colon cancer colo 205 cells through the inhibition of nuclear factor kappa B/p65 and down-regulates cyclooxygenase-2 and matrix metalloproteinase-2 expressions. Anticancer Res. 26 (2006) 1281-1288
46. Aggarwal B.B., Shishodia S., Takada Y., et al. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin. Cancer Res. 11 (2005) 7490-7498
47. Chen A., Xu J., and Johnson A.C. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene 25 (2006) 278-287
48. Huang M.T., Lou Y.R., Ma W., Newmark H.L., Reuhl K.R., and Conney A.H. Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res. 54 (1994) 5841-5847
49. Rao C.V., Rivenson A., Simi B., and Reddy B.S. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res. 55 (1995) 259-266
50. Lev-Ari S., Strier L., Kazanov D., et al. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin. Cancer Res. 11 (2005) 6738-6744
51. Soliva R., Almansa C., Kalko S.G., Luque F.J., and Orozco M. Theoretical studies on the inhibition mechanism of cyclooxygenase-2. Is there a unique recognition site?. J. Med. Chem. 46 (2003) 1372-1382
52. Smith W.L., DeWitt D.L., and Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69 (2000) 145-182
53. Rao C.V., Kawamori T., Hamid R., and Reddy B.S. Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor. Carcinogenesis 20 (1999) 641-644
54. Saltz L.B., Meropol N.J., Loehrer PJ S., Needle M.N., Kopit J., and Mayer R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22 (2004) 1201-1208
55. Chen A., Xu J., and Johnson A.C. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene 25 (2006) 278-287
56. Chen A., and Xu J. Activation of PPAR{Gamma} by curcumin inhibits moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. Am. J. Physiol. Gastrointest. Liver Physiol. 288 (2005) G447-G456
57. Zucker S., and Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev. 23 (2004) 101-117
58. Rao B.G. Recent developments in the design of specific matrix metalloproteinase inhibitors aided by structural and computational studies. Curr. Pharm. Des. 11 (2005) 295-322
59. Hong J.H., Ahn K.S., Bae E., Jeon S.S., and Choi H.Y. The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo. Prostate Cancer. Prostatic Dis. (2006)
60. Lee K.W., Kim J.H., Lee H.J., and Surh Y.J. Curcumin inhibits phorbol ester-induced up-regulation of cyclooxygenase-2 and matrix metalloproteinase-9 by blocking ERK1/2 phosphorylation and NF-kappaB transcriptional activity in MCF10A human breast epithelial cells. Antioxid. Redox Signal. 7 (2005) 1612-1620
61. Atal C.K., Dubey R.K., and Singh J. Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism. J. Pharmacol. Exp. Ther. 232 (1985) 258-262
62. Shoba G., Joy D., Joseph T., Majeed M., Rajendran R., and Srinivas P.S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 64 (1998) 353-356
63. Li L., Braiteh F.S., and Kurzrock R. Liposome-encapsulated curcumin: in vitroand in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104 (2005) 1322-1331
64. Kumar V., Lewis S.A., Mutalik S., Shenoy D.B., Venkatesh, and Udupa N. Biodegradable microspheres of curcumin for treatment of inflammation. Indian J. Physiol. Pharmacol. 46 (2002) 209-217
65. Han G., Xu J., Li W., and Ning C. Study on preparation of the inclusion compound of curcumin with beta-cyclodextrin. Zhong Yao Cai 27 (2004) 946-948
66. Basu N.K., Kole L., Kubota S., and Owens I.S. Human UDP-glucuronosyltransferases show atypical metabolism of mycophenolic acid and inhibition by curcumin. Drug Metab. Dispos. 32 (2004) 768-773
67. Ireson C.R., Jones D.J., Orr S., et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol. Biomarkers Prev. 11 (2002) 105-111
68. Vietri M., Pietrabissa A., Mosca F., Spisni R., and Pacifici G.M. Curcumin is a potent inhibitor of phenol sulfotransferase (SULT1A1) in human liver and extrahepatic tissues. Xenobiotica 33 (2003) 357-363
69. Sugiyama Y., Kawakishi S., and Osawa T. Involvement of the beta-diketone moiety in the antioxidative mechanism of tetrahydrocurcumin. Biochem. Pharmacol. 52 (1996) 519-525
70. Sharma R.A., McLelland H.R., Hill K.A., et al. Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin. Cancer Res. 7 (2001) 1894-1900
71. Cheng A.L., Hsu C.H., Lin J.K., et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 21 (2001) 2895-2900
72. Sharma R.A., Euden S.A., Platton S.L., et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res. 10 (2004) 6847-6854
73. Innocenti F., Liu W., Chen P., Desai A.A., Das S., and Ratain M.J. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacol. Genet. Genomics 15 (2005) 295-301
74. Garcea G., Berry D.P., Jones D.J., et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 120-125
75. Lin L., Shi Q., Su C.Y., Shih C.C., and Lee K.H. Antitumor agents 247. New 4-ethoxycarbonylethyl curcumin analogs as potential antiandrogenic agents. Bioorg. Med. Chem. 14 (2006) 2527-2534
76. Adams B.K., Cai J., Armstrong J., et al. EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs 16 (2005) 263-275
77. Ohtsu H., Xiao Z., Ishida J., et al. Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents. J. Med. Chem. 45 (2002) 5037-5042